Eli Lilly became the first drugmaker to reach a $1 trillion market valuation on Friday, driven by the rapid growth of its ...

Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by ...

Orforglipron is Lilly’s oral GLP-1 in phase 3 development as a treatment for diabetes and obesity. The FDA is expected to approve the drug in March 2026. Lilly’s November news release states that the ...

While heart disease, diabetes and prediabetes are the most common health concerns related to obesity, many other conditions ...

Eli Lilly becomes the first healthcare firm to hit $1T, powered by GLP-1 dominance, surging sales, and strong investor ...

Eli Lilly hit a $1 trillion valuation for the first time, becoming the only healthcare company to reach the milestone as ...

The Indianapolis drug giant's stock (LLY) reached an intraday high of $1,061.17 in morning trading Friday, which was above the threshold of $1,057.78 needed for Lilly to become the 10th U.S. company ...

Eli Lilly hit a $1 trillion valuation, driven by demand for Zepbound and Mounjaro. The first health-care firm ever to join ...

The pharmaceutical giant Eli Lilly's stock has been riding the skyrocketing demand for its weight loss injection Zepbound and diabetes treatment Mounjaro.

The direct-to-employer (DTE) is an industry first for FDA-approved weight-loss drugs like Novo Nordisk's Wegovy (semaglutide) ...

Discover six obesity deals made so far in 2025, with dealmaking activity in the field being largely dominated by big pharma ...

Eli Lilly & Co. and Novo Nordisk A/S plan to start selling their popular obesity shots to employers through a new approach ...